Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
5.89
+0.03 (0.51%)
At close: Jul 11, 2025, 4:00 PM
5.95
+0.06 (1.02%)
After-hours: Jul 11, 2025, 7:57 PM EDT
Quanterix Revenue
Quanterix had revenue of $30.33M in the quarter ending March 31, 2025, a decrease of -5.40%. This brings the company's revenue in the last twelve months to $135.69M, up 7.71% year-over-year. In the year 2024, Quanterix had annual revenue of $137.42M with 12.30% growth.
Revenue (ttm)
$135.69M
Revenue Growth
+7.71%
P/S Ratio
1.67
Revenue / Employee
$288,085
Employees
471
Market Cap
228.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
| Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
| Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
| Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
| Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
QTRX News
- 1 day ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 days ago - Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum - Business Wire
- 20 days ago - Quanterix Expands Reach with IVD and Large Reference Labs - Business Wire
- 4 weeks ago - Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders - PRNewsWire
- 5 weeks ago - Quanterix to Present at Goldman Sachs Global Healthcare Conference - Business Wire
- 7 weeks ago - Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal - PRNewsWire
- 2 months ago - Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Quanterix Releases Financial Results for the First Quarter of 2025 - Business Wire